Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

AR-12286 in Combination With Latanoprost

ClinicalTrials.gov ID: NCT01302249

Public ClinicalTrials.gov record NCT01302249. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).

Study identification

NCT ID
NCT01302249
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aerie Pharmaceuticals
Industry
Enrollment
66 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2011
Primary completion
Nov 30, 2011
Completion
Nov 30, 2011
Last update posted
May 7, 2014

2011

United States locations

U.S. sites
15
U.S. states
13
U.S. cities
14
Facility City State ZIP Site status
David Silverstone, M.D. New Haven Connecticut 06510
Coastal Research Associates, LLC Roswell Georgia 30076
Heart of America Eye Care, P.A. Shawnee Mission Kansas 66204
Taustine Eye Center Louisville Kentucky 40217
Alan L Robin, M.D. Baltimore Maryland 21209
Comprehensive Eye Care St Louis Missouri 63090
Rochester Ophthalmology Group Rochester New York 14618
Glaucoma Consultants of the Capital Region Slingerlands New York 12159
Thomas K. Mundorf, M.D. Charlotte North Carolina 28204
Charlotte Eye Ear Nose and Throat Charlotte North Carolina 28210
The Eye Institute Tulsa Oklahoma 74104
Wills Eye Hospital Philadelphia Pennsylvania 19107
Black Hills Regional Eye Institute Rapid City South Dakota 57701
Cataract & Glaucoma Center El Paso Texas 79902
Stacy R. Smith, M.D. Salt Lake City Utah 84117

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01302249, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2014 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01302249 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →